Peak Bronchoprotection Conferred by Levosalbutamol and Racemic Salbutamol (NAI007)

University of Dundee

Status and phase: Withdrawn; Phase 4

Conditions: Asthma

Treatments: Drug: placebo; Drug: racemic salbutamol; Drug: levosalbutamol

Study type: Interventional

Funder types: Other

Identifiers

NCT00830882

NAI007

Details and patient eligibility

About

The objective of this study is to compare the peak dose relative bronchoprotection offered by levosalbutamol and racemic salbutamol in mild to moderate asthmatics preselected into two groups on the basis of their beta-2 adrenoreceptor polymorphisms.

Sex: All

Ages: 18 to 65 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

1. Mild to moderate stable asthmatics on ≤ 2000μg BDP or equivalent
2. Methacholine responsive PC20< 4 mg/ml
3. >1dd change in methacholine PC20 after the administration of racemic Salbutamol.
4. Male or female 18-65
5. Informed Consent
6. Ability to comply with the requirements of the protocol

Exclusion criteria

1. Severe asthmatics as defined by an FEV1≤ 60% or PEF variability > 30% or with continual daytime or nocturnal symptoms.
2. The use of oral corticosteroids within the last 3 months.
3. Recent respiratory tract infection (2 months).
4. Significant concomitant respiratory disease such as COPD, CF, ABPA, bronchiectasis and active pulmonary tuberculosis.
5. Any other clinically significant medical condition such as unstable angina, acute myocardial infarction in the preceding 3 months, recent TIA/ CVA,that may endanger the health or safety of the participant, or jeopardise the protocol.
6. Any significant abnormal laboratory result as deemed by the investigators
7. Pregnancy, planned pregnancy or lactation
8. Known or suspected contra-indication to any of the IMP's
9. Concomitant use of medicines (prescribed, over the counter or herbal) that may interfere with the trial.

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Crossover Assignment

Masking: Double Blind

---

0 participants in 3 patient groups, including a placebo group

1:levosalbutamol

Experimental group

Description:

2 puffs four times a day for 2 weeks

Treatment:

Drug: levosalbutamol

2: racemic salbutamol

Active Comparator group

Description:

2 puffs four times a day for 2 weeks

Treatment:

Drug: racemic salbutamol

3: Placebo

Placebo Comparator group

Description:

2 puffs four times a day for 2 weeks

Treatment:

Drug: placebo